On 21 August 2019, orphan designation EU/3/19/2192 was granted by the European Commission to TMC Pharma (EU) Limited, Ireland, for setmelanotide for the treatment of Bardet Biedl syndrome.
|Disease / condition||
Treatment of Bardet-Biedl syndrome
|Date of first decision||
|EU designation number||
Review of designation
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see: